Green-Synthesized Gold Nanoparticles Using Pfaffia glomerata Extract Improve Maternal Hypertension and Angiogenic Markers in Pregnant Hypertensive Rats
Background: Hypertensive disorders of pregnancy present a major global health challenge. Green nanotechnology offers a strategy to enhance the stability and efficacy of bioactive natural products. This study evaluated gold nanoparticles green-synthesized with Pfaffia glomerata extract (AuNPs-PG) against gestational hypertension and fetal complications in spontaneously hypertensive rats (SHRs). Methods: P. glomerata root extract was characterized by UHPLC-MS/MS. AuNPs-PG were green-synthesized with 2 mmol/L HAuCl4 (1:5 v/v) at 40 °C and characterized by UV-Vis and DLS. Pregnant Wistar-Kyoto and SHRs were divided into naive, negative control (NC), amlodipine (5 mg/kg), and AuNPs-PG groups (0.03, 0.1, and 0.3 mg/kg) treated daily on gestational days 1–18 to evaluate maternal cardiovascular, renal, biochemical, and reproductive outcomes. Results: UHPLC-MS/MS identified 38 compounds. AuNPs-PG showed a plasmon band at 520–550 nm and 88.1 nm hydrodynamic diameter. In SHRs, 0.3 mg/kg AuNPs-PG reduced systolic blood pressure by 18.5% and mean arterial pressure by 15.4%, while mitigating vascular dysfunction by lowering phenylephrine vasoconstriction by 52.7% and boosting acetylcholine vasodilation by 239.3%. Treatment shortened QTc interval by 26.4%, normalized T-wave inversion, and restored renal excretion, increasing urinary volume by 75.0% and sodium by 94.2%. Furthermore, AuNPs-PG elevated placental growth factor by 180.9%, lowered malondialdehyde by 63.5%, and preserved placental histology. Consequently, mean fetal weight increased by 21.6%, implantation index by 50.5%, and offspring-to-mother ratio by 129.6%. Conclusions: AuNPs-PG (0.3 mg/kg) effectively mitigate maternal and fetal complications in gestational hypertension. Gold nanoparticles serve as nanocarriers, whereas surface-adsorbed phytochemicals drive the biological effects.
Authors
- Otávio Akira Sakai (ORCID: https://orcid.org/0000-0002-3502-5107)
- Maria Luiza Fidelis Silva
- Thainá Aparecida Rafael Silva (ORCID: https://orcid.org/0000-0002-7957-6664)
- Monique Assis de Vasconcelos Barros
- Giselle Nathaly Calaça (ORCID: https://orcid.org/0000-0003-2218-2784)
- Telma Lélia Gonçalves Schultz de Carvalho (ORCID: https://orcid.org/0000-0002-1449-6743)
- Érica Marusa Pergo Coelho
- Arquimedes Gasparotto (ORCID: https://orcid.org/0000-0003-3433-5098)
- Ariany Carvalho dos Santos (ORCID: https://orcid.org/0000-0002-2811-796X)
- Francislaine Aparecida dos Reis Lívero (ORCID: https://orcid.org/0000-0001-6533-0850)
- Luana Ale Bertoncelo Pael (ORCID: https://orcid.org/0009-0002-9133-6249)
- Maria Medina de Azevedo
- J. Miranda (ORCID: https://orcid.org/0000-0002-6951-5788)
- Annye Vitória Moraes (ORCID: https://orcid.org/0009-0003-7543-9501)
- João Pedro Vilella Neto
- Bianca Viana Silva
- Gabriela Pereira da Silva
- Thaylla Bianca de Almeida Vilela (ORCID: https://orcid.org/0009-0004-3900-8154)
- Ana Paula de Carlos Sela
Institutions
- Universidade Estadual de Maringá (BR)
- Universidade Federal da Grande Dourados (BR)
- Universidade Paranaense (BR)
- Instituto Federal do Paraná (BR)
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2026-08-27
- DOI
- https://doi.org/10.3390/pharmaceutics18091074
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul